These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 23478030

  • 1. Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model.
    Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, Lin NN, Wang JM, Chiu YT.
    Lupus; 2013 May; 22(6):554-61. PubMed ID: 23478030
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
    Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G.
    Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
    [Abstract] [Full Text] [Related]

  • 3. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN.
    Lupus; 2002 Aug; 11(7):411-8. PubMed ID: 12195781
    [Abstract] [Full Text] [Related]

  • 4. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
    Ma J, Zhang B, Liu S, Xie S, Yang Y, Ma J, Deng Y, Wang W, Xu L, Li R, Zhang L, Yu C, Shi W.
    PLoS One; 2013 Aug; 8(5):e64912. PubMed ID: 23741418
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
    Zhang B, Xie S, Shi W, Yang Y.
    Nephrol Dial Transplant; 2012 May; 27(5):1746-55. PubMed ID: 22076430
    [Abstract] [Full Text] [Related]

  • 8. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
    Fu J, Wang Z, Lee K, Wei C, Liu Z, Zhang M, Zhou M, Cai M, Zhang W, Chuang PY, Ma'ayan A, He JC, Liu Z.
    Kidney Int; 2018 Feb; 93(2):416-429. PubMed ID: 29102373
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
    Wu MJ, Chang CH, Shu KH, Ho HC, Li JR, Fu YC.
    Transplant Proc; 2014 May; 46(4):1226-8. PubMed ID: 24815166
    [Abstract] [Full Text] [Related]

  • 10. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice.
    Lee SW, Kim BS.
    Clin Exp Rheumatol; 2010 May; 28(3):393-6. PubMed ID: 20497633
    [Abstract] [Full Text] [Related]

  • 11. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE, Korsten P, Koziolek MJ, Niewold TB, Patschan D, Müller GA, Patschan SA.
    Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
    [Abstract] [Full Text] [Related]

  • 12. Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.
    Yung S, Zhang Q, Chau MK, Chan TM.
    Autoimmunity; 2015 Dec; 48(7):471-87. PubMed ID: 26099989
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.
    Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G.
    Kidney Int; 1997 May; 51(5):1583-9. PubMed ID: 9150476
    [Abstract] [Full Text] [Related]

  • 14. Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes.
    Xu LB, Chi N, Shi W.
    Genet Mol Res; 2015 Aug 14; 14(3):9518-29. PubMed ID: 26345885
    [Abstract] [Full Text] [Related]

  • 15. [11R-VIVIT inhibits the expression of urokinase-type plasminogen activator receptor in podocytes].
    Li R, Shi W, Ma J, Zhang B, Zhang L, Liang X, Chen Y, Liu S, Wang W.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul 14; 33(7):1022-6. PubMed ID: 23895845
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis.
    Liao R, Liu Q, Zheng Z, Fan J, Peng W, Kong Q, He H, Yang S, Chen W, Tang X, Yu X.
    PLoS One; 2015 Jul 14; 10(7):e0132724. PubMed ID: 26161538
    [Abstract] [Full Text] [Related]

  • 17. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
    Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D.
    Arthritis Care Res (Hoboken); 2011 Mar 14; 63(3):351-7. PubMed ID: 21080348
    [Abstract] [Full Text] [Related]

  • 18. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L.
    Lupus; 2007 Mar 14; 16(9):707-12. PubMed ID: 17728363
    [Abstract] [Full Text] [Related]

  • 19. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
    Yu CC, Yang CW, Wu MS, Ko YC, Huang CT, Hong JJ, Huang CC.
    J Lab Clin Med; 2001 Jul 14; 138(1):69-77. PubMed ID: 11433230
    [Abstract] [Full Text] [Related]

  • 20. Pim-1 as a Therapeutic Target in Lupus Nephritis.
    Fu R, Xia Y, Li M, Mao R, Guo C, Zhou M, Tan H, Liu M, Wang S, Yang N, Zhao J.
    Arthritis Rheumatol; 2019 Aug 14; 71(8):1308-1318. PubMed ID: 30791224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.